Answers are grounded in this paper and cite their sources.
Objective To understand providers' current teclistamab step-up dosing (SUD) model and how they envision future administration models, as well as perceived barriers and facilitators to these models in day-to-day clinical practice.
No takes yet. Share an insight, caveat, or question.
Derman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: